FDA Issues 14 New GLP-1 Compounder Warning Letters (March-April 2026 Enforcement)

Verified April 11, 2026: The FDA issued 14 new warning letters to GLP-1 compounding pharmacies and telehealth marketers between March 12 and April 8, 2026 — the largest enforcement wave since the April 22, 2025 semaglutide compounding ban took effect. The letters cite violations including unapproved semaglutide salt forms, misleading marketing claims comparing compounded products to Wegovy/Ozempic, and failure to stop production after the shortage was resolved. Affected facilities include 9 state-licensed 503A pharmacies and 5 503B outsourcing facilities. Patients who received prescriptions from these providers should contact their prescriber to verify current sourcing and consider switching to an FDA-approved alternative.

Quick answer: what to do if you were affected.

• •Step 1: Check our FDA Safety Checker — enter your provider's name to see if they're flagged
• •Step 2: Contact your prescriber and ask which pharmacy fills your prescription. If it's on the FDA list, request a switch
• •Step 3: Switch to a verified compliant option. Enhance MD $115-149/mo or Strut Health $149/mo oral use FDA-registered pharmacies under medical-necessity exemptions
• •Step 4: Or switch to brand-name: NovoCare Wegovy $349/mo or LillyDirect Zepbound $299/mo. Telehealth brand alternative: Hers Wegovy $149/mo via the 2026 Novo partnership (cheapest brand Wegovy on the market)
• •Step 5: Report any adverse events to FDA MedWatch at fda.gov/medwatch — this is important for ongoing enforcement

This brings the total FDA warning letters to GLP-1 compounders to 64+ since September 2025, when enforcement began in earnest. For the full legal context see our compounded semaglutide crackdown guide and brand vs compounded GLP-1 guide.

What the FDA Cited (Most Common Violations)

The 14 warning letters issued in March-April 2026 cite four main categories of violations:

• •Continuing to compound semaglutide after the April 22, 2025 enforcement deadline. Six letters cited this. The FDA considers any bulk compounded semaglutide production without a documented patient-specific medical-necessity exemption to be a violation of the FD&C Act.
• •Using semaglutide sodium or semaglutide acetate salt forms. The FDA has explicitly stated these are 'different active ingredients' from the semaglutide base used in Wegovy and Ozempic. Four letters cited this — compounders were selling products that the FDA considers unapproved new drugs.
• •Misleading marketing comparing compounded products to Wegovy/Ozempic. Three letters cited websites or promotional materials claiming 'same as Wegovy' or 'FDA-approved ingredient' when the compounded formulation was materially different. This is considered false advertising under the FTC Act.
• •Improper labeling and record-keeping. One letter cited a 503A pharmacy that had lost batch records, making it impossible to trace which patients received which lots. This is a basic cGMP failure.

Why This Matters for Patients

Three reasons the March-April 2026 enforcement wave is significant beyond just more letters:

• •It targets telehealth marketers, not just pharmacies. Two letters went to telehealth companies that were marketing compounded products through aggressive ads. This signals the FDA is expanding enforcement to the affiliate-style companies that drive compounded volume.
• •Tirzepatide compounding is now in scope. Three of the 14 letters cite tirzepatide, not semaglutide. This is notable because tirzepatide compounding enforcement began in March 2025 but had been less aggressive than semaglutide. The gap has closed.
• •Enforcement is accelerating, not slowing down. Prior to September 2025, the FDA issued warning letters at a rate of roughly 2-3 per month. The March-April wave is 14 in 27 days — a 5x acceleration. This suggests the agency has built internal capacity for the crackdown.

How to Verify Your Current Provider Is Compliant

If you're on a compounded GLP-1 today, here are the questions to ask your provider:

• •Which pharmacy fills my prescription? The answer should be a specific 503A or 503B pharmacy name, not 'our network' or 'our partner'.
• •Is that pharmacy on the FDA warning letter list? You can verify at fda.gov/warning-letters or use our Safety Checker.
• •Under what medical-necessity exemption is this compounded? A compliant provider will point to a specific documented exemption (allergy to PEG inactive ingredients, specific dose escalation requirement, combination therapy needed). 'Cost savings' is NOT a valid exemption.
• •Which active ingredient is used? Acceptable answer: semaglutide base or tirzepatide base. UNACCEPTABLE answers: 'semaglutide sodium', 'semaglutide acetate', or any salt form. These are FDA-flagged as unapproved new drugs.

If your provider can't clearly answer any of these, that's a signal to switch. Our FDA Safety Checker has a verified compliant providers list with current pharmacy partnerships documented.

Sources